Report Overview

The South Korea Gaucher disease market size stood at around USD xx billion in 2019 and is projected to reach xx billion by 2028, exhibiting a CAGR of around 2.9 % during the forecast period.

Gaucher disease is a rare genetic disorder, classified into three clinical subtypes, wherein an enzyme called glucocerebrosidase does not work correctly and cannot break down a lipid called glucocerebroside. Glucocerebroside then accumulates in the body and affects various parts, including the bone marrow, liver, bone, lung, and spleen, among others. Type 1 is the most common and less severe, while type 2 and 3 are more severe because they affect the brain and spinal cord. In Asian countries, including Korea, more than 50 percent of patients suffer from type 2 and 3 Gaucher disease.



Market Drivers

Prevalence of Gaucher disease is high in Korea. In particular, the prevalence of type 3 Gaucher disease is 38.9 percent in Korea, which is significantly higher than the global prevalence of 5 percent. This is the primary factor driving the market growth. Additionally, continuous clinical trials going on rare disorders and increased demand of drugs for the treatment of rare disorders will boost up the Gaucher disease market. However, due to rare disorders difficulty in clinical trials and stringent FDA guidelines for the approval of new treatment or drugs may hamper the global Gaucher disease market.